Enhancing hemophilia A management: emicizumab as a cost-effective adjunct to standard therapy for inhibitor patients

Authors

  • Vishnu Sharma Department of Clinical Hematology, SMS Medical College, Jaipur, Rajasthan, India
  • Vansh Bagrodia Department of Medicine, SMS Medical College, Jaipur, Rajasthan, India
  • Aayush Kulshreshtra Department of Medicine, NIMS University, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20241000

Keywords:

Hemophilia A, Emicizumab, Low dose recombinant factor VIIa, Inhibitors pharmacoeconomics

Abstract

This case report discusses the cost-effectiveness of emicizumab + low dose recombinant factor VIIa (rFVIIa) therapy in management of mild hemophilia A with inhibitors. Initial treatment with recombinant factor VIII was complicated by inhibitor development, leading to recurrent bleeding and hematoma formation. After administering full dose rFVIIa to patient for controlling bleeding episodes initially, patient was transitioned to emicizumab alongside low-dose recombinant factor VIIa, which proved efficacious and cost-effective. This case highlights the potential of emicizumab to alleviate the financial burden on patients and healthcare systems, improving treatment access and outcomes for a broader hemophilia patient population.

References

Castaman G, Peyvandi F, De Cristofaro R, Pollio B, Di Minno DMN. Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs. J Clin Med. 2023;12(4):1368.

Giuffrida AC, Genesini S, Franchini M, De Gironcoli M, Aprili G, Gandini G. Inhibitors in mild/moderate haemophilia A: two case reports and a literature review. Blood Transfus. 2008;6(3):163-8.

Linari S, Castaman G. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence. Ther Clin Risk Manag. 2020;16:461-9.

Kinra P, Kumar H. Recombinant Factor VIIA. Med J Armed Forces India. 2009;65(1):59-61.

Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377(9):809-18.

Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology & social costs of haemophilia in India. Indian J Med Res. 2014;140(1):19-31.

Downloads

Published

2024-04-25

How to Cite

Sharma, V., Bagrodia, V., & Kulshreshtra, A. (2024). Enhancing hemophilia A management: emicizumab as a cost-effective adjunct to standard therapy for inhibitor patients. International Journal of Basic & Clinical Pharmacology, 13(3), 395–397. https://doi.org/10.18203/2319-2003.ijbcp20241000

Issue

Section

Case Reports